IDYA - IDEAYA Biosciences

-

$undefined

N/A

(N/A)

IDEAYA Biosciences NasdaqGS:IDYA IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Location: 5000 Shoreline Court, South San Francisco, CA, 94080, United States | Website: https://www.ideayabio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.089B

Cash

692.5M

Avg Qtr Burn

-66.03M

Short % of Float

12.31%

Insider Ownership

0.91%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Darovasertib Details
Uveal melanoma

Phase 3

Initiation

Darovasertib (IDE196) + crizotinib Details
Solid tumor/s, Metastatic uveal melanoma, Cancer

Phase 2/3

Data readout

Darovasertib Details
Cancer, Ocular melanoma

Phase 2

Data readout

Darovasertib (IDE196) + crizotinib Details
Solid tumor/s, Metastatic uveal melanoma, Cancer, Cutaneous Melanoma

Phase 2

Data readout

IDE397 (MAT2A) Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma, Bladder cancer

Phase 1/2

Data readout

Phase 1/2

Update

Phase 1

Data readout

IDE397 (MAT2A) + Trodelvy Details
MTAP-Deletion Urothelial Cancer

Phase 1

Data readout

IDE161 +/- KEYTRUDA® (pembrolizumab) Details
Solid tumor/s, Cancer, ER+/HER2- breast cancer, Ovarian cancer, Endometrial cancer

Phase 1

Update

IDE275 (GSK959) Details
Solid tumor/s, Cancer

Phase 1

Initiation

IDE397 (MAT2A) +/- AMG 193 Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma

Failed

Discontinued